Embo Molecular Medicine
Publication date:
2021-08-09
Volume:
13
Publisher:
Wiley
Author:
Lalli, Giovanna
Schott, Jonathan M ; Hardy, John ; De Strooper, Bart
Keywords:
Science & Technology, Life Sciences & Biomedicine, Medicine, Research & Experimental, Research & Experimental Medicine, Alzheimer Disease, Amyloid beta-Peptides, Antibodies, Monoclonal, Humanized, Humans, Immunotherapy, 06 Biological Sciences, 11 Medical and Health Sciences, 3101 Biochemistry and cell biology
Abstract:
On 7 June, the FDA approved aducanumab, the first new drug for Alzheimer's disease in almost 20 years-and notably, the first drug with a putative disease-modifying mechanism for the treatment of this devastating disorder, namely the removal of β-amyloid (or Aβ) plaques from the brain.